Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia
Category: #health  By Pankaj Singh  Date: 2019-10-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia

Vertex Pharmaceuticals Inc. is a global biopharmaceutical company that is relentless in striving for medical excellence while developing transformative therapies for life-threatening and serious diseases, such as cystic fibrosis. It has made a name for itself by investing in various scientific innovations.

However, recently the firm made headlines when it announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) will be reimbursed in Australia for people suffering from CF (cystic fibrosis) that are homozygous for the F508del mutation or who have an instance of the F508del mutation along with a different responsive RF (residual function) mutation in the CFTR gene.

Reportedly, patients with the second condition would be able to obtain medicine for their cause for the first time. Moreover, ORKAMBI® (lumacaftor/ivacaftor) will be reimbursed to children suffering from CF between the ages 2 to 5 and those who have dual copies of the F508del mutation in their CFTR gene. People above 6 years already have access to ORKAMBI® since October 2018 in Australia.

Speaking on the move, Ludovic Fenaux, Senior Vice President, Vertex International, said that the company is pleased to share that ORKAMBI® and SYMDEKO® will become immediately accessible to patients with cystic fibrosis in Australia.

Moreover, the company appreciates PBAC (Pharmaceutical Benefits Advisory Committee) for recognizing the worth of these drugs to patients and the company extends its appreciation to the Minister for Health and the Department of Health in Australia for their solid collaboration and engagement to complete the agreement, cites Fenaux.

However, this news comes at the heels of recent management change in the company. Earlier this year, Vertex had revealed that Carmen Bozic, M.D., would serve as the firm’s Executive Vice President of Global Medical Affairs and Medicines Development.

Additionally, Dr. Bozic will fulfill the additional role of Chief Medical Officer (CMO), as the current CMO Reshma Kewalramani takes up the position of President and Chief Executive Officer.

Source Credit: https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-reimbursement-cystic-fibrosis-medicines



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
By Pankaj Singh

Epizyme, Inc., a renowned biopharmaceutical company developing new epigenetic therapies, has reportedly announced that the United States Food and Drug Administration has granted the accelerated approval of the company&...

PayPal and UnionPay partner to expand their global consumer base
PayPal and UnionPay partner to expand their global consumer base
By Pankaj Singh

Digital payment applications have simplified cashless transactions by offering payment options in both offline and online mode. Within a short span of time, the digital payment industry has seen significant growth, wit...

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...